Johnson And Johnson Talc Verdict Puts Legal Risks And Valuation In Focus

Simply Wall St

Tue, February 17, 2026 at 8:12 AM GMT+9 3 min read

In this article:

JNJ

-0.45%

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.

Johnson & Johnson (NYSE:JNJ) was found liable by a Philadelphia jury in an ovarian cancer case linked to long term use of its talc based baby powder.

The jury awarded compensatory and punitive damages to the family of a woman who died from ovarian cancer.

This case is one of over 70,000 similar lawsuits consolidated in federal court, with more trials scheduled for 2026.

The verdict comes as medical authorities increasingly recognize a probable cancer risk from genital talc use, and recent studies reinforce this association.

Johnson & Johnson, a global healthcare company with products across pharmaceuticals, medical devices, and consumer health, now faces heightened scrutiny around its talc portfolio. The Philadelphia ruling adds legal pressure at a time when scientific and regulatory attention on talc and cancer risk is building. This matters for both litigation exposure and brand perception.

For investors watching NYSE:JNJ, the key questions are how future trials unfold, how courts treat scientific evidence, and what this means for potential settlement structures or product decisions. The scale of the more than 70,000 consolidated cases, together with the company’s past attempts to address talc claims through bankruptcy processes, keeps legal risk and reputational considerations firmly in focus.

Stay updated on the most important news stories for Johnson & Johnson by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Johnson & Johnson.

NYSE:JNJ 1-Year Stock Price Chart

Is Johnson & Johnson’s balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis.

Investor Checklist: Johnson & Johnson After the Talc Verdict

Quick Assessment

**⚖️ Price vs Analyst Target**: At US$243.45, JNJ trades about 5% above the US$231.25 analyst price target.

**✅ Simply Wall St Valuation**: Our model suggests the shares are trading roughly 36.4% below estimated fair value.

**✅ Recent Momentum**: The stock has returned about 11.3% over the last 30 days.

There is only one way to know the right time to buy, sell or hold Johnson & Johnson. Head to Simply Wall St’s company report for the latest analysis of Johnson & Johnson’s fair value.

Key Considerations

📊 The Philadelphia ruling keeps legal and reputational risk around talc at the center of the JNJ equity story, even as the broader business spans pharmaceuticals and medical devices.

📊 Watch how future talc trial outcomes, any settlement frameworks, and updates to risk disclosures intersect with JNJ’s US$26.8b net income and 28.5% margin profile.

⚠️ The large pipeline of talc cases and evolving scientific evidence could influence future cash outflows, product decisions, and how investors assess JNJ’s risk premium.

 






Story Continues  

Dig Deeper

For the full picture including more risks and rewards, check out the complete Johnson & Johnson analysis. Alternatively, you can check out the community page for Johnson & Johnson to see how other investors believe this latest news will impact the company’s narrative.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include JNJ.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info